Acute ischemic stroke and long-term outcome after thrombolysis: Nationwide propensity score-matched follow-up study

Stroke

Volumn 45, Issue 10, 2014, Pages 3070-3072

  Schmitz, Marie Louise ^a   Simonsen, Claus Z ^a   Hundborg, Heidi ^a   Christensen, Hanne ^b   Ellemann, Karsten ^c   Geisler, Karin ^d   Iversen, Helle ^e   Madsen, Charlotte ^f   Rasmussen, Mary Jette ^g   Vestergaard, Karsten ^h   Andersen, Grethe ^a   Johnsen, Soeren P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

^d HOLSTEBRO HOSPITAL   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g Esbjerg University Hospital   (Denmark)

^h AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

mortality; therapeutic thrombolysis; tissue type plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHARLSON COMORBIDITY INDEX; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPENSITY SCORE; RECURRENCE RISK; VERY ELDERLY; ADOLESCENT; COMPLICATION; DENMARK; FIBRINOLYTIC THERAPY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGISTER; STROKE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DENMARK; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922481782     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006570     Document Type: Article

References (13)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet. 2007;369:275-282.
4. Dirks M, Niessen LW, van Wijngaarden J, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, et al; PRACTISE Investigators. The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice. Int J Stroke. 2012;7:289-292.
5. Gensicke H, Seiffge DJ, Polasek AE, Peters N, Bonati LH, Lyrer PA, et al. Long-term outcome in stroke patients treated with IV thrombolysis. Neurology. 2013;80:919-925.
6. Schmülling S, Grond M, Rudolf J, Heiss WD. One-year follow-Up in acute stroke patients treated with rtPA in clinical routine. Stroke. 2000;31:1552-1554.
7. Fischer U, Mono ML, Zwahlen M, Nedeltchev K, Arnold M, Galimanis A, et al; QABE Investigators. Impact of thrombolysis on stroke outcome at 12 months in a population: The Bern stroke project. Stroke. 2012;43:1039-1045.
8. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787.
9. IST-3 Collaborative Group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12:768-776.
10. Wildenschild C, Mehnert F, Thomsen RW, Iversen HK, Vestergaard K, Ingeman A, et al. Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients. Clin Epidemiol. 2014;6:27-36.
11. Dansk Selskab for Apopleksi, DSfA. Referenceprogram for Behandling af Patienter med Apopleksi. Version 3. 0 ed. København: Dansk Selskab for apopleksi, DSfA; 2009.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
13. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med. 2007;26:20-36.